AbbVie’s latest trading data shows ABBV stock price advancing on increased institutional accumulation. Volume spiked 18% above 30-day average, often interpreted as a bullish confirmation in equity markets. AbbVie is up 36.3% since the beginning of the year, and at $244.50 per share, has set a new 52-week high. Investors who bought $1,000 worth of AbbVie’s shares 5 years ago would now be looking at an investment worth $2,806. AbbVie ( NYSE:ABBV - Get Free Report ) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. During the same quarter in the previous year, the firm posted $2.65 earnings per share. The company's revenue for the quarter was up 6.6% on a year-over-year basis. As a group, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year. AbbVie Dividend Announcement 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Wednesday, October 15th will be paid a $1.64 dividend. This represents a $6.56 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Wednesday, October 15th. AbbVie's dividend payout ratio is currently 312.38%. Insider Activity at AbbVie In other news, EVP Nicholas Donoghoe sold 13,295 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total value of $2,639,190.45. Following the transaction, the executive vice president directly owned 58,247 shares of the company's stock, valued at $11,562,611.97. The trade was a 18.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website . Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the transaction, the executive vice president directly owned 177,292 shares in the company, valued at $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The disclosure for this sale can be found here . Corporate insiders own 0.25% of the company's stock. Institutional Trading of AbbVie Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company's stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares during the last quarter. Geode Capital Management LLC increased its position in shares of AbbVie by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company's stock valued at $7,240,169,000 after buying an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of AbbVie by 6.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company's stock valued at $4,970,848,000 after buying an additional 1,517,222 shares in the last quarter. Norges Bank bought a new stake in shares of AbbVie in the 2nd quarter valued at $4,288,200,000. Finally, Northern Trust Corp increased its position in shares of AbbVie by 0.9% in the 1st quarter. Northern Trust Corp now owns 22,013,920 shares of the company's stock valued at $4,612,357,000 after buying an additional 189,294 shares in the last quarter. Institutional investors own 70.23% of the company's stock. AbbVie Company Profile ( Get Free Report ) AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. See Also Five stocks we like better than AbbVie Dividend Capture Strategy: What You Need to Know After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Best ESG Stocks: 11 Best Stocks for ESG Investing Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Top Stocks Investing in 5G Technology Forget Airlines—These Trucking Stocks Are Shifting Into High Gear This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]. Should You Invest $1,000 in AbbVie Right Now? Before you consider AbbVie, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list. While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here (Almost) Everything You Need To Know About The EV Market Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential. Get This Free Report The ABBV stock price momentum remains positive as Relative Strength Index hovers near 62, suggesting moderate bullish sentiment. Recent pipeline advancements could accelerate revenue growth projections for 2024–2025.